Aridis Pharmaceuticals, Inc. (ARDS)
- GlobeNewswire
Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock
Los Gatos, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,000,000 shares of the Company’s common stock at a purchase price of $0.38 per share in a registered direct offering. The closing of the offering is expected to occur on or about March 16, 2023, subject to the satisfaction of customary closing conditions. H.C. W
- GlobeNewswire
Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as
- Simply Wall St.
When Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Aridis Pharmaceuticals...
